Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis

Journal of the Neurological Sciences

Volumn 155, Issue 1, 1998, Pages 1-12

  Shi, Fu Dong ^a   Bai, Xue Feng ^a   Xiao, Bao Guo ^a   Van Der Meide, Peter H ^b   Link, Hans ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Active suppression; Cytokine; Experimental autoimmune encephalomyelitis; Experimental autoimmune myasthenia gravis; Experimental autoimmune neuritis; Nasal tolerance

Indexed keywords

CHOLINERGIC RECEPTOR; MYELIN BASIC PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; ENCEPHALOMYELITIS; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTRANASAL DRUG ADMINISTRATION; MYASTHENIA GRAVIS; NEURITIS; NONHUMAN; PERIPHERAL NERVE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SCIATIC NERVE; SPINAL CORD; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CATTLE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; FEMALE; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYELIN BASIC PROTEINS; MYELIN SHEATH; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032542558     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00232-3     Document Type: Article

References (52)

1. Aarli A., Milde E.J., Thunold S. Arthritis in myasthenia gravis. J. Neurol. Neurosurg. Psych. 38:1975;1048-1055.
2. Asthana D., Fujiii Y., Huston Y., Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin. Immunol. Immunopathol. 67:1993;240-248.
3. Bai X.F., Shi F.D., Jie Z., Xiao B.G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
4. Balasa B., Deng C.S., Christadoss P., Bradley L.M., Sarvetnick N. IFN-γ is essential for the genesis of acetylcholine receptor induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 96:1997;385-391.
5. Chen Y.-H., Inobe J.-I., Marks R., Gonnella P., Kuchroo V.K., Weiner H.L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 376:1995;177-180.
6. Chen Y.-H., Inobe J.-I., Weiner H.L. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediated active suppression. J. Immunol. 155:1995;910-916.
7. Christadoss P., Lindstrom J., Munro S., Talal N. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlation with cellular, humoral and clinical responses. J. Neuroimmunol. 8:1985;29-41.
8. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T cell deletion in high dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
9. Deibler G.E., Martensson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:1972;139-164.
10. Dick A.D., Cheng Y.F., McKinnon A., Liversidge J., Forrester J.V. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. Br. J. Ophthalmol. 77:1993;171-175.
11. Drachman D.B. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve. 19:1996;1239-1251.
12. Goldman M., Herode A., Borenstein S., Zanean A. Optic neuritis, transverse myelitis, and anti-DNA antibodies nine years after thimectomy for myasthenia gravis. Arthritis Rheum. 27:1984;701-703.
13. Gu D., Wogensen I., Calcultt N.A., Xia C., Zhu S., Merlie J.P., Fox H.S., Lindstrom J., Powell C.H., Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J. Exp. Med. 181:1995;547-557.
14. Graus Y.M.F., van Breda Vriesman P.J.C., De Baets M.H. Characterization of anti-AChR antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 92:1993;506-513.
15. Harrison L.C., Dempsey-collier M., Kramer D.R., Takahashi K. Aerosol insulin induces regulatory CD8 γδT cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184:1996;2167-2174.
16. Hofman F.M., Yanagihara E.Y., Byrne B., Billing R., Baird S., Frisman D., Taylor C.R. Analysis of B cell antigens in normal reactive lymphoid tissue using four B cell monoclonal antibodies. Blood. 62:1983;775-783.
17. Husby S., Mesterdy J., Holland S., Elson C.O. Oral tolerance in human: T cell but not B cell tolerance after feeding. J. Immunol. 152:1994;4664-4670.
18. Jelinek D.F., Lipsky P.E. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor alpha and interleukin 1. J. Immunol. 139:1987;2970-2979.
19. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann. NY Acad. Sci. 274:1976;283-299.
20. Lindstrom J., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology. 26:1976;1054-1059.
21. Link H., Olsson O., Sun J.B., Wang Z.Y., Andersson G., Ekre H.P., Brenner T., Abramsky O., Olsson T. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87:1991;2191-2196.
22. Link J., Söderström M., Ljungdahl Å., Höjeberg B., Olsson T., Xu Z.S., Fredrikson S., Wang Z.Y., Link H. Organ-specific autoantigens induce IFN-γ and IL-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology. 44:1994;728-735.
23. Krolick K.A., Zoda T.E., Thompson P.A. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv. Neuroimmunol. 4:1994;475-493.
24. Ma C.-G., Zhang G.-X., Xiao B.-G., Link J., Olsson T., Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:1995;51-60.
25. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods. 106:1988;191-194.
26. Massague J. The transforming growth factor-β family. Annu. Rev. Cell. Biol. 6:1990;597-641.
27. Matusevicius D., Navikas V., Palask W., Pirskanen R., Fredrikson S., Link H. Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71:1996;191-198.
28. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 178:1993;889-899.
29. Melmaed D., Fredman A. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. Eur. J. Immunol. 24:1994;1974-1981.
30. Metzler B., Wraith D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int. Immunol. 5:1993;1159-1165.
31. Metzler B., Wraith D.C. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 778:1996;228-243.
32. Miller A., Lider O., Roberts A.B., Sporn M.B., Weiner H.L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β following antigen-specific triggering. Proc. Natl. Acad. Sci. USA. 89:1992;421-425.
33. Mondino A., Khoruts A., Jenkins M.K. The anatomy of T-cell activation and tolerance. Proc. Natl. Acad. Sci. USA. 93:1996;2245-2252.
34. Mowat A. McI. The regulation of immune responses to dietary protein antigens. Immunol. Today. 8:1987;93-98.
35. Norton W.I., Poduslo S.E. Myelination rat nerve: Method of myelin isolation. J. Neurochem. 21:1973;749-757.
36. Ohtsuru I., Matsuo H., Fukudome T., Suenaga A., Tsujihata M., Nagataki S. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis: implication for design of specific immunotherapies. Clin. Exp. Immunol. 102:1995;462-467.
37. Okumura, S., McIntosh, K., Drachman, D.B., 1994. Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis. 36, 704-713.
38. Petterson J.D., Kapus W.J., Miller S.D. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur. J. Immunol. 23:1993;46-55.
39. Rizzo I.V., DeKruyff R.H., Umetso D.T. Generation of B cell memory and affinity maturation: Induction with Th1 and Th2 cell clones. J. Immunol. 148:1992;3733-3738.
40. Sakaguchi S., Toda M., Asano M., Itoh M., Moores S.S., Sakaguchi N. T cell-mediated maintenance of nature self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9:1996;211-220.
41. Shi F.D., Zhang G.X., Bai X.F., van der Meide P.H., Link H. Cellular mRNA expression of IFN-γ, IL-4 and IL-10 related to resistance to experimental autoimmune myasthenia gravis in young Lewis rats. Clin. Exp. Immunol. 108:1997;523-527.
42. Sidman C.L., Marshall J.D., Gray P.W., Johson H.M. γ-Interferon is one of the several direct B cell-maturing lymphokines. Nature. 309:1984;801-803.
43. Snapper C.M., Mond J.J. Toward a comprehensive view of immunoglobulin class swithching. Immunol. Today. 14:1993;15-17.
44. Stokes C.R., Newby T.J., Bourne F.J. The influence of oral immunization on local and systemic immune responses to heterologous antigens. Clin. Exp. Immunol. 52:1983;399-406.
45. Tola M.R., Caniatti L.M., Casetta I., Granieri E., Conighi C., Quatrale R., Monetti V.C., Paolino E., Govoni V., Pascarella R., Carreras M. Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. Acta Neurol. Scand. 90:1994;318-323.
46. Vistica B.P., Chanaud N.P., Felix N., Caspi R.R., Rizzo L.V., Nussenblatt R.B., Gery I. CD8 T-cells are not essential for the induction of 'low-dose' oral tolerance. Clin. Immunol. Immunopathol. 78:1996;196-202.
47. Wang Z.-Y., Link H., Huang W.-X. T-cell immunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis. Scand. J. Immunol. 37:1993;615-622.
48. Wang Z.-Y., Link H., Ljungdahl Å., Höjeberg B., Link J., Qiao J., Melms A., Olsson T. Induction of interferon-γ, interleukin-4 and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 157:1994;353-368.
49. Wang Z.-Y., He B., Qiao J., Link H. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetycholine receptor and myelin basic protein: double tolerance. J. Neuroimmunol. 63:1995;79-86.
50. Whitacre C.C., Gienapp I.E., Meyer A., Cox K.L., Javed N. Treatment of autoimmune diseases by oral tolerance to autoantigens. Clin. Immunol. Immunopathol. 80:1996;31-39.
51. Wraith D.C. Antigen-specific immunotherapy of autoimmune disease: a commentary. Clin. Exp. Immunol. 103:1996;349-352.
52. Zhang, G.X., Xiao, B.G., Bai, X.F., Örn, A., Van der Meide, P.H., Link, H., 1997. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. Submitted.